BioInvent signs deal with Bayer HealthCare for the discovery and development of therapeutic antibodies
BioInvent International AB (OMXS: BINV) announced that it has signed a deal with Bayer HealthCare related to the discovery and development of antibody products. Under the terms of the agreement, Bayer HealthCare will have a non-exclusive research licence for the use of BioInvent's proprietary n-CoDeR® library for the discovery of human monoclonal antibodies. BioInvent, in addition to its n-CoDeR® technology, will provide at BioInvent access to an extended antibody technology suite including BioInvent's proprietary selection processes, streamlined robotics and Immunoglobulin transient Expression technology. Bayer HealthCare will fund all such activities.
As well as undisclosed license fees, BioInvent will receive additional milestone payments and escalating royalties on sales of any products commercialised. The agreement allows for up to 14 antibody products to be developed.
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Last viewed contents
RVX-208 Exploratory Study Illustrates Early Potential for Alzheimer's Disease
US FDA Accepts Genmab's A/S IND for HuMax-CD20 to Treat Active Rheumatoid Arthritis
Blocking the active site of thiolase - Scientists at the University of Oulu, Finland, and at the HZB break new ground for drug discovery research in the fight against sleeping sickness
Jerini AG reaches milestones in two research alliances with Baxter Healthcare
Genzyme Corporation to Acquire ILEX Oncology, Inc. - Takes Important Step to Establish Oncology Franchise
Key player identified in cascade that leads to hypertension-related kidney damage
Addex Parkinson's Product Progressing in Early Clinical Trials
Brain glia cells increase their DNA content to preserve vital blood-brain barrier
Pevion appoints Didier Hoch as Chairman of the Board
